Skip to main content
. 2020 Oct 17;89(1):42–53. doi: 10.1002/ana.25917

TABLE 1.

Baseline Characteristics of Ischemic Stroke Patients with Atrial Fibrillation According to Prior Anticoagulation Therapy

Characteristic All patients with AF (n = 8,179) Patients with AF without anticoagulation (n = 5,059) Vitamin K antagonists
All (n = 1,486) INR ≤1.7 (n = 609) INR >1.7 (n = 877) DOACs (n = 1,634) p a
Age, yr n = 8,179, 79.8 ± 9.6 n = 5,059, 79.4 ± 10.1 n = 1,486, 81.3 ± 8.2 n = 609, 82.1 ± 7.8 n = 877, 80.7 ± 8.4 n = 1,634, 79.8 ± 8.9 <0.001
Sex, male n = 8,173, 4207 (51%) n = 5,055, 2,558 (51%) n = 1,485, 766 (52%) n = 608, 279 (46%) n = 877, 487 (56%) n = 1,633, 883 (54%) 0.051
Body mass index, kg/m2 n = 5,745, 25.8 ± 4.6 n = 3,637, 25.8 ± 4.6 n = 1,029, 26.0 ± 4.6 n = 402, 25.7 ± 4.3 n = 627, 26.3 ± 4.7 n = 1,079, 25.8 ± 4.7 0.202
Previous ischemic stroke, yes n = 8,100, 1784 (22%) n = 4,998, 847 (17%) n = 1,473, 401 (27%) n = 602, 163 (27%) n = 871, 238 (27%) n = 1,629, 536 (33%) <0.001
Previous transient ischemic attack, yes n = 8,093, 578 (7%) n = 4,998, 281 (6%) n = 1,470, 146 (10%) n = 599, 46 (8%) n = 871, 100 (11%) n = 1,625, 151 (9%) <0.001
Previous intracerebral hemorrhage, yes n = 8,101, 195 (2%) n = 5,000, 131 (3%) n = 1,474, 31 (2%) n = 603, 12 (2%) n = 871, 19 (2%) n = 1,627, 33 (2%) 0.281
Hypertension, yes n = 8,132, 6,823 (84%) n = 5,018, 4,092 (82%) n = 1,482, 1,306 (88%) n = 605, 545 (90%) n = 877, 761 (87%) n = 1,632, 1,425 (87%) <0.001
Diabetes mellitus, yes n = 8,127, 1,868 (23%) n = 5,016, 1,060 (21%) n = 1,480, 406 (27%) n = 604, 165 (27%) n = 876, 241 (28%) n = 1,631, 402 (25%) <0.001
Dyslipidemia, yes n = 8,079, 5,001 (62%) n = 4,990, 2,975 (60%) n = 1,469, 964 (66%) n = 600, 384 (64%) n = 869, 580 (67%) n = 1,620, 1,062 (66%) <0.001
Smoker, yes n = 8,020, 978 (12%) n = 4,932, 649 (13%) n = 1,469, 140 (10%) n = 602, 49 (8%) n = 867, 91 (10%) n = 1,619, 189 (12%) 0.001
Onset to hospital time, min n = 7,670, 591.8 ± 1331.1 n = 4,754, 554.7 ± 1289.7 n = 1,397, 603.0 ± 1328.5 n = 578, 400.6 ± 1302.8 n = 819, 745.8 ± 1328.6 n = 1,519, 697.8 ± 1451.0 0.001
INR value n = 1450, 1.9 (1.5; 2.4) n = 609, 1.4 (1.2; 1.6) n = 841, 2.3 (2.0; 2.8)
Glucose, mmol/l n = 6,720, 7.3 ± 2.9 n = 4,159, 7.3 ± 2.9 n = 1,221, 7.3 ± 2.5 n = 483, 7.2 ± 2.4 n = 738, 7.3 ± 2.6 n = 1,340, 7.2 ± 3.0 0.743
Blood pressure, systolic, mmHg n = 7,850, 155.5 ± 27.7 n = 4,841, 156.2 ± 27.9 n = 1,434, 154.2 ± 27.1 n = 586, 154.4 ± 27.4 n = 848, 154.0 ± 26.9 n = 1,575, 154.2 ± 27.9 0.007
Blood pressure, diastolic, mmHg n = 7,846, 85.4 ± 18.2 n = 4,837, 85.9 ± 18.3 n = 1,436, 85.1 ± 18.2 n = 586, 84.8 ± 18.2 n = 850, 85.2 ± 18.2 n = 1,573, 84.4 ± 17.9 0.018
a

Univariate comparison between controls, all vitamin K antagonists and DOACs.

AF = atrial fibrillation; DOACs = direct oral anticoagulants; INR = international normalized ratio.